ArticleMicrobial biotechnology2026
Feasibility and Safety of Washed Microbiota Transplantation as Salvage Therapy for Refractory Non-CDI Gut Pathogens in Critically Ill Patients.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03895593 (Rescue Fecal Microbiota Transplantation for Refractory Intestinal Infections), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rescue Fecal Microbiota Transplantation for Refractory Intestinal Infections: China National Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Limited treatment options exist for refractory non-Clostridioides difficile infection (non-CDI) of the gut in critically ill patients; whether washed microbiota transplantation (WMT) is feasible and safe in this heterogeneous population is unknown. We retrospectively analysed prospectively registered consecutive cases (NCT03895593) between September 2015 and August 2022, in which severe non-CDI gut pathogens were identified, and rescue WMT was administered after standard treatment failure. Primary outcomes were the clinical outcome and adverse events graded by CTCAE v5.0. Secondary descriptive outcomes were the change in total abdominal symptom score (TASS) on day 7, microbiological clearance, and 12-week survival. Ten patients underwent 29 WMT infusions. Fifty percentage of patients (5/10) obtained clinical cure after WMT. Twenty percentage of patients (2/10) achieved clinical improvement and 30% (3/10) showed no response 7 days after WMT. One transient WMT-related fever occurred (1/29, 3.45%). No serious WMT-attributed events were observed. TASS decreased significantly (p = 0.007). Microbiological clearance was documented in 3 of 4 patients with available post-WMT stool bacteriological test results. This case series provides preliminary evidence supporting the feasibility and potential efficacy of WMT for refractory non-CDI gut pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.